Alnylam announces $1 billion buyback and change in commercial leadership
FROM THE WIRE · BUSINESSWIRE.COM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA $1 billion buyback signals management confidence and can support the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The board authorized a $1 billion share repurchase program.
- 02The company will transition to new commercial leadership for its next growth phase.
- 03Chair Amy Schulman said the decisions show conviction in Alnylam's future.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets